Coverage of Novel Therapies for Non-Hodgkin's Lymphoma and Multiple Myeloma in Brazil and Mexico Hinges on Demonstrating Clinical and Economic Benefit Versus MabThera and Velcade - News and Weather For The Quad Cities -

Coverage of Novel Therapies for Non-Hodgkin's Lymphoma and Multiple Myeloma in Brazil and Mexico Hinges on Demonstrating Clinical and Economic Benefit Versus MabThera and Velcade

  • Most Popular StoriesMost Popular StoriesMore>>

  • Thomson Prison Gets Ready To Hire With Job Fair

    Thomson Prison Gets Ready To Hire With Job Fair

    Tuesday, September 2 2014 3:35 PM EDT2014-09-02 19:35:36 GMT
    The Federal Bureau of Prisons just announced it will be holding a job fair for a variety of jobs at the U.S. Penitentiary in Thomson, Ill. And it's not just prison guards that are needed.More >>
    The Federal Bureau of Prisons just announced it will be holding a job fair for a variety of jobs at the U.S. Penitentiary in Thomson, Ill. And it's not just prison guards that are needed.
    More >>
  • John Deere Road Motorist Ends Up In Corn Field

    John Deere Road Motorist Ends Up In Corn Field

    Tuesday, September 2 2014 2:38 PM EDT2014-09-02 18:38:22 GMT
    One person was involved in an early morning accident in Rock Island County. The driver wound up on the edge of a cornfield just off John Deere Road near Silvis, Ill.More >>
    One person was involved in an early morning accident in Rock Island County. The driver wound up on the edge of a cornfield just off John Deere Road near Silvis, Ill.More >>
  • Woman Taken To Hospital After ATV Crash On Wapsipinicon Sandbar

    Woman Taken To Hospital After ATV Crash On Wapsipinicon Sandbar

    Monday, September 1 2014 4:50 PM EDT2014-09-01 20:50:56 GMT
    Scene Of ATV Accident Saturday near Calamus, IAScene Of ATV Accident Saturday near Calamus, IA
    Conservation officers are reminding people to stay away from sandbars when using All-Terrain-Vehicles following a weekend accident.More >>
    Conservation officers are reminding people to stay away from sandbars when using All-Terrain-Vehicles following a weekend accident.More >>

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Decision Resources Group

Public Healthcare Systems in Brazil and Mexico Cover Targeted Therapies but with Indication-Specific Restrictions, According to Findings from Decision Resources Group

BURLINGTON, Mass., June 9, 2014 /PRNewswire/ -- Decision Resources Group finds that targeted therapies such as MabThera (rituximab) for non-Hodgkin's lymphoma (NHL) and Velcade (bortezomib) for multiple myeloma (MM) enjoy extensive but incomplete coverage in Brazil and Mexico through complex mechanisms. To obtain reimbursement, novel therapies for these indications must show head-to-head clinical benefits and improved cost-effectiveness (or other pharmacoeconomic benefits such as reduced budgetary impact) against these standards of care. However, meeting these requirements may become increasingly challenging because each of these markets has already welcomed a copy biologic or a generic version of these agents. Nonetheless, as the prevalence of NHL and MM continues to grow with the aging populations of Brazil and Mexico, the need for novel, more tolerable and effective agents increases.  

Decision Resources Group Logo.

Other key findings from the Emerging Markets Physician and Payer Forum report entitled The Impact of LATAM (Brazil and Mexico) Payer Policy on Prescribing in Non-Hodgkin's Lymphoma and Multiple Myeloma include:

  • In Brazil, the government is promoting the domestic production of biosimilars, such as rituximab biosimilars, to reduce health expenditures and promote industry.
  • In Mexico, the coverage of NHL and MM agents varies between the national public healthcare institutions, ranging from requiring out-of-pocket payment or prior-authorization to readily providing therapies at no cost to covered patients.
  • Patient shares of agents for NHL and MM are substantially different between the public and private sectors in Brazil and Mexico. In the public sector of both countries, patients with certain NHL subtypes versus others benefit from greater coverage.

Comments from Decision Resources Group Analyst Solsire Zevallos, Ph.D.:

  • "Payers in Brazil and Mexico will grant formulary coverage to novel agents for NHL and MM that demonstrate clinical benefit and cost-savings to their health care systems. Although novel oral therapies such as Novartis' panobinostat offer savings on infusion costs, this may be curtailed by co-administration with IV therapies. On the other hand, Roche's Gazyva (obinutuzumab) and Bristol-Myers Squibb/AbbVie's elotuzumab are novel IV therapies that are favored by payers and physicians for their clinical efficacy." 
  • "The entrance of generic versions of Velcade and biosimilar versions of MabThera may complicate the formulary inclusion of novel agents in the national public healthcare systems of Brazil and Mexico. However, certain public institutions in these markets are able to provide greater coverage, and the private sector-which is substantial and growing rapidly in Brazil-will continue to prefer branded agents."

Upcoming webinar:

  • Media members are welcome to attend our upcoming webinar based on this report entitled Non-Hodgkin's Lymphoma and Multiple Myeloma in LATAM: How are Physicians and Payers Managing Patient Access to MabThera and Velcade? This presentation will be held on Tuesday, July 15, 2014. For more information, please contact Christopher Comfort at ccomfort@dresourcesgroup.com.

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow

805 Brady Street, Davenport, IA 52803

Telephone: 563.383.7000
Fax: 563.383.7131
Email: news@kwqc.com

Can’t find something?
Powered by WorldNow
All content © Copyright 2000 - 2014 Young Broadcasting of Davenport, Inc. A Media General Company.